Immunome, Inc. (NASDAQ:IMNM – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $27.20 and last traded at $26.9050, with a volume of 128841 shares changing hands. The stock had previously closed at $26.14.
Analyst Ratings Changes
IMNM has been the topic of a number of research analyst reports. Truist Financial began coverage on shares of Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 price objective on the stock. Stephens raised their price objective on Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a research note on Monday, November 17th. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Guggenheim increased their target price on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, Evercore ISI boosted their price target on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.00.
View Our Latest Analysis on Immunome
Immunome Price Performance
Immunome (NASDAQ:IMNM – Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. As a group, sell-side analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.
Insiders Place Their Bets
In related news, Director Isaac Barchas sold 383,200 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares in the company, valued at $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Philip Tsai acquired 10,000 shares of the company’s stock in a transaction on Friday, December 19th. The shares were purchased at an average cost of $20.49 per share, with a total value of $204,900.00. Following the completion of the purchase, the insider directly owned 43,300 shares of the company’s stock, valued at $887,217. This trade represents a 30.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 68,518 shares of company stock valued at $1,453,958 over the last ninety days. 7.69% of the stock is owned by insiders.
Hedge Funds Weigh In On Immunome
Hedge funds have recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in Immunome in the fourth quarter worth about $64,000. Assetmark Inc. bought a new stake in shares of Immunome during the 3rd quarter worth approximately $39,000. BIT Capital GmbH bought a new stake in shares of Immunome during the 3rd quarter worth approximately $69,000. BNP Paribas Financial Markets boosted its holdings in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in Immunome in the 3rd quarter valued at $76,000. 44.58% of the stock is currently owned by institutional investors.
About Immunome
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Recommended Stories
- Five stocks we like better than Immunome
- The day the gold market broke
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Punch these codes into your ordinary brokerage account
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Gold’s getting scarce.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
